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Background/Aim: Tendinopathies are pathological conditions of tissue remodelling occurring in the major
tendons of the body, accompanied by excessive nociceptive signalling. Tendinopathies have been shown to exhibit
an increase in the number of mast cells, which are capable of releasing histamine, tryptase and other substances
upon activation, which may play a role in the development of tendinopathies. This study set out to describe the
distribution patterns of a family of receptors called protease-activated receptors (PARs) within the Achilles tendon.
These four receptors (PAR1, PAR2, PAR3, PAR4) are activated by proteases, including tryptase released from mast
cells, and are involved in fibrosis, hyperalgesia and neovascularisation, which are changes seen in tendinopathies.
Method: In order to study which structures involved in tendinopathy that these proteases can affect, biopsies from
patients suffering of mid-portion Achilles tendinosis and healthy controls were collected and examined using
immunohistochemistry. Tendon cells were cultured to study in vitro expression patterns.
Results: The findings showed a distribution of PARs inside the tendon tissue proper, and in the paratendinous
tissue, with all four being expressed on nerves and vascular structures. Double staining showed co-localisation of
PARs with nociceptive fibres expressing substance P. Concerning tenocytes, PAR2, PAR3, and PAR4, were found in
both biopsies of tendon tissue and cultured tendon cells.
Conclusions: This study describes the expression patterns of PARs in the mid-portion of the Achilles tendon, which
can help explain the tissue changes and increased pain signalling seen in tendinopathies. These findings also show
that in-vitro studies of the effects of these receptors are plausible and that PARs are a possible therapeutic target in
the future treatment strategies of tendinopathy.
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Tendinopathy is a pathological condition of pain and tis-
sue remodelling occurring in the major tendons of the
body, such as the Achilles tendon. The condition is com-
monly thought to originate from overuse of the tendon,
as it often afflicts people with a high level of physical ac-
tivity, although additional aetiological factors have been
suggested, such as anatomical predisposition as well as
obesity and a lack of physical activity [1-3]. Certain* Correspondence: gustav.andersson@umu.se
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unless otherwise stated.histological traits within the tendon tissue characterize
the condition, including hypercellularity, angiogenesis,
and increased collagen production [4] (see Figure 1). A
histological verified diagnosis with these changes is
sometimes called tendinosis [4,5]. This is accompanied
by an excessive nociceptive signalling from the tendon,
causing pain and restricted mobility [6]. The mecha-
nisms behind these structural and neurological changes
are not fully understood. Earlier theories were based pri-
marily on classical inflammation (i.e. “tendinitis”) and
collagen damage as the main aetiological factors; how-
ever, in later years new hypothesis have arisen, suggest-
ing that other pathways are involved [4,7]. A more
recent theory ascribes part of the tendinosis changes tontral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Histological differences between normal and
tendinosis tendon. The normal tendon shows organised collagen
fibres and a sparse amount of tendon cells, tightly packed between
the collagen bundles (A). In tendinosis (B), the tendon structure gets
disorganised, the tenocytes change morphology and proliferate.
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substance P (SP), within tendinosis tissue [8].
Protease-activated receptors (PARs) are a relatively
newly discovered group of receptors believed to be
involved in the regulation of numerous processes
within the human body [9,10]. This family of G protein-
coupled receptors consists of four known members
(PAR 1–4) that are enzymatically activated by proteolysis
of a specific target site on the receptor (see Figure 2).
This proteolysis unmasks a tethered ligand attached to
the receptor, which in turn activates the receptor [11].
Numerous types of cells have been shown to express
PARs such as fibroblasts, neurons, endothelial cells, and
mast cells, among others [11]. The involvement of this
receptor family has been implicated in the pathophysi-
ology of conditions such as pancreatitis, arthritis, can-
cer, and lung fibrosis [10,12-15]. Common activators
of PARs in vivo are trypsin, tryptase, and thrombin
[11]. Mast cells contain high amounts of tryptase and,
therefore, act as one of the main activators of several
PARs in vivo [10].
Interestingly, activation of PARs in tissue types other
than tendon has been shown to generate several of the
characteristic traits that are typical for tendinosis. Thesechanges include fibroblast proliferation [10,14,16-18],
angiogenesis [10,19], changes in collagen expression
[14,16], and an increased local release of SP [20,21]. Fur-
thermore, a pro-nociceptive effect has been described in
which activation of PARs may lead to a sensitization of
afferent nerve fibres [13,21-23]. A link between the re-
ported effects of these receptors and the pathology of
tendinosis is that recent studies have shown an increase
in the number of mast cells in tendinotic tissue and sug-
gest a local effect involved in tendinopathies [24-26]. As
tryptase is a known potent activator of PARs [10],
degranulating mast cells are possible activators of PARs
also concerning tendons.
The possible occurrence and disposition of PARs in re-
lation to tendon tissue is yet to be examined/described.
In this study, we therefore aimed to define the expres-
sion patterns of PARs on different structures in relation
to the Achilles tendon, including the tenocytes them-
selves–both in vivo and in vitro.
Materials and method
Biopsies
Tissue biopsies were collected from the Achilles tendon
from a total of 26 individuals. Of these, 22 individuals
had a documented history of chronic Achilles tendon
pain with subsequent impairment of movement. Doppler
ultrasound examination showed increased intratendi-
nous blood flow as well as a disorganized collagen struc-
ture within the Achilles tendon of these 22 patients,
confirming the diagnosis of tendinosis according to
established diagnostic criteria [27]. The diagnosis was
further established by histological examination following
surgery showing hypercellularity, changed tenocyte
morphology, and loss of collagen structure within the
tendon, indicative of tendinosis [4]. Harvest of the tendi-
notic biopsies was performed in concert with patients
undergoing surgical treatment for their Achilles tendino-
sis. 3 of the tendinosis patients donating tendon tissue
had undergone prior treatments consisting of injections
of a sclerosing substance (polidocanol) in the paratendi-
nous tissue surrounding the Achilles tendon. An
additional 4 tissue biopsies were collected from healthy
individuals volunteering to donate tissue samples.
Healthy controls were defined as individuals without his-
tory of Achilles tendon pain and/or signs of Achilles ten-
dinosis during Doppler ultrasound examination. All
donors were otherwise healthy, non-smokers, and on no
medication at the time of surgery.
All tissue samples were collected in strict sterile condi-
tions from the ventral side of the mid-portion of the
Achilles tendon (the most affected site in tendinosis pa-
tients) using a lateral incision during local anaesthesia.
Biopsies were directly placed in sterile saline solution
and immediately taken to the laboratory to be prepared
Figure 2 Activation of protease-activated receptors. The protease-activated receptors are a family of G-coupled receptors which are activated
through proteolytic cleaving (A) which unmasks a tethered ligand. This ligand then activates the receptor (B) which causes an intracellular signal
to be transduced (C). Original art by Gustav Andersson.
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biopsies, 21 were chosen for histological sectioning
and staining (Table 1) while 5 biopsies were used for
cell culture experiments (Table 2). The surgeries, as
well as the ultrasound examinations, were performed
by Prof H. Alfredson.
The study was approved by the Regional Ethical Review
Board in Umeå and was performed according to the princi-
ples of the declaration of Helsinki (http://www.epn.se/en/).
All donors had given informed consent prior to donation.
Histological preparations
Biopsies were either fixed by immersion overnight at
4°C, in 4% (w/v) formaldehyde 0.1 M phosphate buf-
fer, pH 7.0, and then washed in the isotonic salt so-
lution Tyrode’s solution (containing 10% (w/v) sucrose)
before being mounted on thin cardboard using OCT em-
bedding medium (Miles Laboratories, Naperville, IL, USA)
and snap-frozen in liquid nitrogen chilled propane, or im-
mediately frozen without fixation. Samples were then
stored at–80°C prior to sectioning and staining. Sectioning
was done using a cryostat producing sections of 7 μm
thickness, which were mounted on chrome-alum-gelatine
pre-treated slides. Notably, a few biopsies consisted of in-
sufficient amount of tissue to provide sections to stain all
four PAR-receptors (PAR-1 n=20, PAR-2 n=20, PAR-3
n=19, PAR-4 n=19).
Sections were stained according to an established
protocol [28]. Four polyclonal rabbit antibodies specific
for each respective PAR receptor were used, and a
monoclonal mouse antibody for SP, all at concentrations
of 1:100 (see Table 3). The frozen sections were initially
allowed to thaw for 10 minutes at room temperature.
After this the samples were submerged in 1% (v/v) triton
X-100 solution for 20 minutes for permeabilisation,followed by 3x5min washing in phosphate buffered sa-
line (PBS). Incubation with swine normal serum was
performed at a concentration of 1:20 for 15 minutes
prior to an overnight incubation with the primary anti-
body at 4°C. The sections were then washed for an add-
itional 3x5min in PBS followed by a second incubation
with swine normal serum 1:20 for 15 minutes. This was
followed by an incubation with a secondary swine anti-
rabbit antibody conjugated with tetramethylrhodamine-
5-(and 6)-isothiocyanate (TRITC) (Dako, Copenhagen
DN; R0156), for fluorescent detection, at a concentration
of 1:40 for 30 minutes at 37°C. Finally, a series of washes
with PBS as mentioned in previous text was performed
followed by mounting of the sections using Vectashield
(Vector Labs, Burlingame, CA, USA; H-1200) containing
4’,6-diamidino-2-phenylindole (DAPI) for nuclear coun-
ter staining. Control stainings were performed by re-
placing the primary antibody with PBS to control for
unspecific antigen binding of the secondary antibody.
Double staining with SP involved additional steps of
washing in PBS following the incubation of the secondary
antibody towards the PAR-antibody, as described above,
and incubation in donkey normal serum 1:20 for 15 mi-
nutes, and then incubation with the primary SP antibody
overnight at 4°C. The subsequent steps where then repeated
as for the solitary PAR-staining described above, with the
supplementation of swine normal serum with donkey
normal serum and the secondary antibody with a
donkey anti-mouse antibody conjugated with 1:500
Alexa Fluor® 488 dye (Invitrogen, CA, USA: A-21202).
Histological evaluation
All sections were inspected using a Zeiss Axioscop 2
Plus microscope equipped with epifluorescence and an
Olympus DP70 digital camera. Expression of PAR-1,-2,-3




Age (years) Sex Diagnosis Prior tendinosis
treatment
Fixation
A1 45 Male Tendinosis None No
A2 41 Male Tendinosis None No
A3 59 Female Tendinosis None No
A4 49 Male Tendinosis None No
A5 37 Female Tendinosis None No
A6 68 Female Tendinosis None Yes
A7 44 Female Tendinosis None No
A8 45 Female Tendinosis None No
A9 27 Male Tendinosis None No
A10 34 Male Tendinosis None No
A11 51 Female Tendinosis None No
A12 56 Female Tendinosis Polidocanol
treatment
No
A13 57 Female Tendinosis Polidocanol
treatment
No
A14 67 Male Tendinosis None No
A15 45 Female Tendinosis None No
A16 47 Female Tendinosis None No
A17 58 Female Tendinosis Polidocanol
treatment
No
A18 48 Male Healthy None No
A19 28 Male Healthy None Yes
A20 23 Male Healthy None Yes
A21 21 Male Healthy None Yes
n=21. 10 males, 11 females. Mean age 42.2 years (SD 13.3).
Fixation: treated with formaldehyde (see ‘Histological preparations’).
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GA) independently of each other. The examiners were
blinded as to whether the biopsies came from healthy or
tendinotic tendons, however, the receptor evaluated was
not blinded for. Three specific structures of interest
within the biopsies–tenocytes, vessels, and nerves–were
selected due to their involvement in tendinosis pathology
[4,27], and given a semi-quantitative score of 0–3 based onTable 2 Patient information of tissue samples used for
cell culture
Patients n=5 Age (years) Sex Diagnosis Prior tendinosis
treatment
B1 33 Male Tendinosis None
B2 40 Male Tendinosis None
B3 55 Male Tendinosis None
B4 53 Male Tendinosis None
B5 45 Male Tendinosis None
n=5. 5 males, 0 females. Mean age 45.2 years (SD 9.1).the intensity of fluorescence and amount of reactive struc-
ture. Not all biopsies displayed the specific structures pre-
viously mentioned and in these cases they were not given a
score for that structure. All samples were photographed
for documentation. The results from each observer were
pooled together yielding a mean score for each PAR-
receptor in the respective tissue structure of interest.
Evaluation of co-localisation of PARs and SP was per-
formed to see if PARs are expressed on nociceptive fibres
in the tendon related tissues. No immunohistochemical
staining was performed to differentiate tenocytes or vessels
in this study. Parallel sections stained with H&E were used
to identify structures in cases of uncertainty.
Human tendon cell culture
Human Achilles tendon biopsies were initially washed in
Hanks balanced salt solution (HBSS) and, by means of a
scalpel, cleared of any visible tissue that was not of the
tendon tissue proper. The biopsies were then manually
divided into smaller pieces and enzymatically digested
using a collagenase solution (Clostridopeptidase A,
C-0130 Sigma) diluted in D-MEM (Invitrogen; 11960) at
a concentration of 2 mg/ml. The product was centrifuged
to obtain a cell pellet and supernatant. The supernatant
was discarded and the cell pellet was washed in HBSS
and later dissolved in media consisting of Dulbecco’s
Modified Eagle Medium (D-MEM) supplemented with
10% (v/v) foetal bovine serum (FBS), 1% (v/v) pen-strep
antibiotics and 0.2% (v/v) L-Glutamine. This solution was
portioned out in cell culture flasks and stored in a hu-
midified environment at 37°C/5% (v/v) CO2. Media was
replaced every 72 h. As soon as cells reached confluence
in the culture flasks they were passaged and split into
new flasks in a 1:3 ratio. Cells were used for immunohis-
tochemical stainings at passage 3–5 by seeding them on
glass slides over night. The immunohistochemical stain-
ing was carried out in the same manner as described
under ‘Histological preparations’, following a 10 min fix-
ation in 3% (v/v) paraformaldehyde. This protocol has
been shown to produce a tendon cell phenotype, as veri-
fied by earlier studies [29].
Results
Histological appearance
The biopsies taken from tendinosis patients displayed clas-
sical signs of tendinosis: hypercellularity, changed cell
morphology, and loss of tissue structure, as well as signs of
newly formed vessels in the tendon tissue itself. Not all
structures of interest were featured in every biopsy. This
can be derived from the fact that therapeutic surgery on
Achilles tendinosis consists of scraping of the ventral
border of the tendon, sometimes resulting in biopsies with
a scarce amount of tendon tissue proper and varying
amounts of paratenon and other paratendinous structures.
Table 3 Antibodies used for detection of PAR 1–4 and Substance P
Target Code Source Raised in Concentrations used
PAR-1 APR-031 Alomone Labs, Jerusalem, Israel Rabbit 1:100
PAR-2 APR-032 Alomone Labs, Jerusalem, Israel Rabbit 1:100
PAR-3 ab66068 Abcam, Cambridge UK Rabbit 1:100
PAR-4 ab66103 Abcam, Cambridge UK Rabbit 1:100
Substance P 8450-0505 AbD Serotec, Oxford, UK Mouse 1:100
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normal tendon tissue proper and paratenon, i.e. no
hypercellularity, normal tenocyte morphology, and nor-
mal tendon tissue structure. No evident vascular changes
were seen in these biopsies.
Incidence and disposition of PAR 1–4
No statistical significant differences were seen between
the healthy controls and the tendinosis tendons concerning
the degree of PAR-expression in the different structures of
interest when subjecting the data to non-parametric statis-
tical tests. The results of the immunohistochemical evalua-
tions are presented in Table 4.
PAR-1 was not expressed on tenocytes, in tissue sec-
tions or in cultured tenocytes (Figure 3A and B), on any
of the slides investigated. The receptor was detected atTable 4 Scores from evaluation of tendon biopsies
NORMAL TENDONS (n=4)
PAR-1 PAR-2 PAR-3 PA
Tenocytes
n 3 3 3 3
Mean 0.0 2.7 2.5 1.3
SD 0.0 0.3 0 0.3
Median 0.0 2.5 2.5 1.5
IQR 0.0 2.5-2.8 2.5-2.5 1.3-
Vessels
n 4 4 4 4
Mean 1.6 2.3 2.3 2.8
SD 0.3 0.3 0.3 0.5
Median 1.5 2.3 2.3 3.0
IQR 1.5-1.6 2-2.5 2.0-2.5 2.8-
Nerves
n 3 2 4 4
Mean 3.0 1.8 1.5 2.4
SD 0.0 0.4 0.6 0.5
Median 3.0 1.8 1.5 2.3
IQR 2.0-3.0 1.6-1.9 1.0-2.0 2.0-
n: number of samples containing structure of interest, SD: Standard deviation, IQR:
for each receptor.relatively low level on vessels (Figure 3C, mean score of
normal tendons (MSn): 1.6, mean score of tendinosis
tendons (MSt): 1.0), but was frequently expressed in
nerve fibres (Figure 3D, MSn: 3.0, MSt: 2.2).
PAR-2 was detected on tenocytes both in vitro
(Figure 4A) and in biopsies (Figure 4B, MSn: 2.7, MSt:
2.8). It was also expressed in some nerves (Figure 4D,
MSn: 1.8, MSt: 1.5) and vessels (Figure 4C, MSn: 2.3,
MSt: 1.8). This suggests a presence of PAR-2 in all three
structures of interest, but the strongest reactions were
seen in the tenocytes themselves. Concerning nerves,
they were quite scarcely expressed, and only a fraction of
the samples showed clear immunofluorescence when the
nerves were stained for PAR-2 (cf. Table 4).
PAR-3 also stained positive on tenocytes in vitro
(Figure 5A) and in biopsies (Figure 5B, MSn: 2.5, MSt: 1.4),TENDINOSIS TENDONS (n=17)
R-4 PAR-1 PAR-2 PAR-3 PAR-4
Tenocytes
12 12 11 11
0.0 2.8 1.4 1.5
0.0 0.45 0.6 0.7
0.0 3.0 1.5 1.5
1.5 0.0 2.9-3.0 1.0-1.8 1.0-1.75
Vessels
14 12 15 15
1.0 1.8 2.2 2.4
0.4 0.6 0.3 0.4
1.5 2.0 2.0 2.5
3.0 1.5-1.6 1.5-2.0 2.0-2.5 2.0-2.5
Nerves
9 4 2 10
2.2 1.5 1.0 2.4
0.8 0.6 0.0 0.4
2.0 1.5 1.0 2.3
2.6 2.0-3.0 1.0-2.0 1.0-1.0 2.0-2.5
interquartile range. Bold number represent most prominent reactive structure
Figure 3 PAR-1 expression in tendon tissue and cultured cells. PAR-1 immunostaining (red) was not found in tenocytes (arrow) in either
tissue sections from tendon biopsies (B) or in cultured cells (A). DAPI-combined-staining (blue) is shown in (A) to visualize cells without reactive
staining for PAR-1. Any red staining in (A) and (B) is considered background staining and not specific reactions. Vessels (asterisk in C) and nerve
fibres (N) in (D) were clearly reactive. B is a healthy tendon section, C & D are from tendinosis.
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1.5, MSt: 1.0) were reactive. The receptor was most evident
in vessels (Figure 5C, MSn: 2.3, MSt: 2.2).
Lastly, PAR-4 displayed a staining pattern similar to
that of PAR-2 and–3, staining positively on tenocytes
in vitro (Figure 6A) and in biopsies (Figure 6B, MSn: 1.3,
MSt: 1.5). The staining of nerves (Figure 6D, MSn: 2.4,
MSt: 2.4) and vessels (Figure 6C, MSn: 2.8, MSt: 2.4)
was stronger than seen for the tenocytes. The staining
pattern found on tenocytes for PAR-4 appeared to be
not only weaker but also in closer relation to the nucleus
as compared to PAR-2 and–3, which showed a homoge-
neous staining of the whole tenocyte.Figure 4 PAR-2 expression in tendon tissue and cultured cells. Positive
(asterisk in C & D), and nerve fibres (N in D), as well as in tendon biopsies (Double stainings of the PAR-receptors and SP showed
that nerve fibres and fascicles expressing the PAR-
receptors often co-localised with SP (Figure 7A-H). Not
all the nerve fibres expressing PARs were positive for SP.
Discussion
Our study shows that all the four protease-activated re-
ceptors are expressed in human tendon tissue to varying
levels and distributions of expression. Nerve fibres ex-
pressing PARs were co-localised with SP–a marker for
nociceptive fibres–but were also expressed on nerve fi-
bres not showing SP-positive reactions. This shows that
other nerves than nociceptive ones may be regulated byimmunostaining for PAR-2 (red) in cultured tenocytes (A) vessels
arrow in B). All sections (B-D) are from healthy tendons.
Figure 5 PAR-3 expression in tendon tissue and cultured cells. Positive reactions for PAR-3 (red) shown in cultured tenocytes (A), tenocytes
in biopsies (arrow in B), vessels (asterisk in C & D), as well as in nerve fibres (N in D). B & C are sections showing tendinosis, D is from a healthy tendon.
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seems to be similar in tendinosis tendon tissue and in
healthy tendons, although this study lacked sufficient bi-
opsies from healthy donors to make an adequate com-
parison between the groups. It is important to note that
the technique of immunofluorescence employed in this
study cannot be used to compare the amount of the in-
dividual receptors against each other, but only when
comparing the localisation of the same receptor in the
same sample. However, the extent to which the recep-
tors showed immunofluorescence in the different tissue
types studied (tenocytes, nerves and vessels) can hint at
where they have the most effect. Of note is also that only
6 out of the 21 biopsies studied showed evident nerve
fibre reactions for PAR2 and PAR3, which could beFigure 6 PAR-4 expression in tendon tissue and cultured cells. PAR-4 stai
tenocytes in vivo (arrow in B), vessels (asterisk in C), and nerve fibres (N in D). D
for PAR-4 in close relation to nuclei. All sections (B-D) are from tendinosis tendexplained by the specific sections actually not containing
any nerves. Perhaps these receptors are not expressed
on all kinds of nerves, but this study shows a co-
localisation on SP-positive fibres, which are considered
nociceptive.
Conclusions
PAR-1 was mainly found on nerves and to a lesser ex-
tent on vessels within tendon tissue. The receptor was
not seen on tenocytes, indicating that this receptor does
not have a direct effect on these cells. In a study on
breast cancer, PAR-1 was differentially expressed on
stromal fibroblasts and in the healthy fibroblasts the re-
ceptor was not expressed whereas activated fibroblast
started to express the receptor [30]. PAR-1 agonists cannings showing positive results (red) on tenocytes in culture (arrow in A),
API-combined-staining is shown in A to visualize cells with weak staining
ons.
Figure 7 Double stainings for PARs and substance P. A-D shows PARs [1-4] and E-H shows corresponding SP-staining; PAR-1 (A) is co-localised
with SP-positive nerve fibres (E) (arrows). The same was seen for PAR-2 (nerve fascicle in B&F), PAR-3 (nerve fascicle in C&G) and PAR-4 (D&H, arrows
show perivascular nerve fibres).
Figure 8 Interaction of mast cell with tissues involved in
tendinosis. Mast cells are recruited to the tendon tissue in cases of
tendinosis, the mechanism behind which is unclear. A possible
attractant is neuropeptides, such as SP (red dots), which can be
produced by the tenocytes or released from peripheral nerve
endings. These neuropeptides are also capable of causing the mast
cells to degranulate, where upon tryptase and other proteases
(blue dots) can affect the tendon, vessels and nerves via the
protease-activated receptors. Original art by Gustav Andersson.
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flow, but has also been connected to angiogenesis [32].
Other studies have shown that PAR-1 is involved in sen-
sitising nociceptive neurons [33], pain signalling and
neurogenic inflammation [11,34,35] by direct effect on
nerve fibres, functions that could be of importance in
tendinosis pathology as neurogenic inflammation has
been implied as one of the contributors to tendinopa-
thies [36]. On the other hand, a study be Martin et al.
[37] found that the effects of PAR-1 stimulation caused
an inhibition of inflammatory pain through activation of
endogenous opioid pathways in the peripheral tissue it-
self. If the same can be seen in tendon tissues, this could
potentially give rise to localised treatments with PAR-1
agonists as pain relief in tendinosis patients.
PAR-2 is known to be involved in many processes
similar to those that occur in tendinosis, in other tissues.
These processes include fibroblast proliferation [10,14,16],
angiogenesis [10,19], hyperalgesia [23], changes in collagen
expression [14,16], and an increased, local release of
SP [20,21]. In our study, PAR-2 was identified within
all three cell-types/structures of interest. Since this re-
ceptor is activated by tryptase, a protease abundant in
mast cells, and there is a known increase in mast cell
numbers in tendinosis tendon tissue [24], the discov-
ery of PAR-2 expression within tendon tissue makes it
logical to presume that this receptor can play a role in
tendon pathology. The PAR-2 expression on vascular
structures could be linked to a possible role in the
angiogenesis described for tendinopathy, as other stud-
ies have shown that PAR-2 agonists can drive angio-
genesis in an in-vivo ischemia model [38]. Studies
have shown PAR2 to be co-localised with TRPV1 re-
ceptors and cause hyperalgesia [39].
PAR-3 was found on all three cell-types/structures of
interest. Unlike PAR-1,–2 and–4, there are few known
effects of PAR-3 stimulation other than that it acts as a
co-receptor for PAR-4 [11,40].PAR-4 was also found on nerves, vessels and teno-
cytes. This receptor has mainly been implicated in pain
modulation by direct effect on nerve fibres where it
seems to be able to sensitize as well as desensitize nerve
fibres depending on the environment in which the
receptor is activated [22,33,41]. This pain modulating ef-
fect could be of importance in tendinosis development,
considering that increased tendon pain is one of the
cardinal symptoms of the condition.
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vessels were seen predominantly in the tissues outside of
the tendon tissue proper. These structures have been de-
scribed earlier [42] and are targeted in novel treatment
strategies directed at the ventral side of the Achilles ten-
don, such as ultrasound-guided scraping [27,43,44]. This
fact may have caused an undersampling of the neuronal
PAR expression in this study, as most biopsies contained
tendon tissue proper and only smaller parts of the para-
tendinous tissues, such as; epitenon, paratenon and the
loose connective tissue ventral to the tendon. Future
studies on neuronal PAR expression may want to focus
on these tissues as the tendon tissue proper is mostly
devoid of nerve fibres [45].
As was stated in the introduction, tendon cells have
been shown to produce and release SP [8,28], a neuro-
peptide involved in pain-transmission and neurogenic
inflammation [46]. It is also known that SP can attract
mast cells and cause them to degranulate [47,48]. A part
in the “biochemical” hypothesis for tendinopathy could
therefore include the interplay between locally produced
neuropeptides, such as SP, and the attraction and de-
granulation of mast cells (see Figure 8).
As this study has shown that tenocytes in culture have
similar expression patterns of PARs as they do in vivo, it
is possible to study the effects of PAR-activation on
tenocytes in an in vitro setting. By better understanding
the mast cell and PAR interaction in tendinopathies,
treatment of these conditions could come to include
mast cell stabilizing agents such as over-the-counter
allergy medicines, or directed PAR agonists and antago-
nists which are under development [49,50]; both of
which could become important therapeutic tools.
In summary, protease-activated receptors are expressed
in the Achilles tendon and surrounding tissues. PAR-1
and–4 was found most frequently in nerves, whereas
PAR-2 was expressed primarily by tenocytes. All four
PARs where expressed on vessels in and around the
tendon. All four PARs co-localised with SP-positive nerve
fibres. More control samples are needed to study whether
healthy and tendinosis tendons display varying degrees of
PAR expression, as no significant difference was seen in
this study. Further studies are needed to decide what ef-
fects the activation of the individual receptors may have
in the development and possible treatment of tendinosis.
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